
LL-BMT1 is a sustained drug delivery approach via a 3D-printed, drug-eluting contact lens to be used in glaucoma care that successfully completed a Phase 2b clinical trial.

LL-BMT1 is a sustained drug delivery approach via a 3D-printed, drug-eluting contact lens to be used in glaucoma care that successfully completed a Phase 2b clinical trial.

Ashley Mills, The Vision Council CEO, outlines new additions to the show that are unveiling what is to come in terms of fashion, technology, and patient care.

At the Envision Summit 2025 in San Juan, Puerto Rico, Sherrol Reynolds, OD, FAAO, participated in a discussion on patient-centered care and the newest treatment strategies in neovascular AMD and DME.

At the Envision Summit 2025 in San Juan, Puerto Rico, Ashley Wallace Tucker, OD, FAAO, FSLS, gave insight into advancements in keratoconus management and the importance of early detection as well as tips and advice on fitting scleral contact lens

At the Envision Summit 2025 in San Juan, Puerto Rico, Jessica Steen, OD, FAAO talked with glaucoma surgeons on the importance of comanaging patients throughout their lifetime.

Catch up on the top stories in optometry during the week of February 10-February 14.

According to a news release from the company, the VR platform “disrupt[s] traditional diagnostic methods by offering an untethered, all-in-one diagnostic solution that includes a variety of tests such as visual field, progression analysis, color sensitivity, and now visual acuity testing.”

The Vision Council CEO Ashley Mills overviews what is new and exciting at this year's show, running from February 19-22 in Orlando, Florida, and provides a free registration code for those still looking to register.

Practice Compliance Solutions, CodeSAFEPLUS, Practice Resource Management, and EyeCode Education have formed Practice Performance Partners.

The research team conducted a prospective study to assess any barriers to parental compliance with vision testing in preschoolers aged 3 to 6 years in hopes of catching amblyopia earlier.

The approval follows a refiling after the FDA issued a Complete Response Letter due to language on the amended label.

Walline, OD, PhD, FAAO, outlines how to predict myopia progression and delay its onset in an exclusive interview with Optometry Times.


Toronto-based Cellview currently designs and manufactures highly performant diagnostic imaging instruments that leverage internal R&D expertise, according to a news release.

The review “illuminates the pressing need for further research into this sight-threatening condition, particularly prospective, randomized, or well controlled cohort studies,” according to its authors.

Jeffrey Walline, OD, PhD, FAAO, overviews a presentation he gave on the Bifocal Lenses in Nearsighted Kids 2 (BLINK2) cohort study at the Collaborative Community on Ophthalmic Innovation (CCOI).

The device was created in collaboration with SlitLED and featuring AutoAquire, RemotePilot, and Multi-Slit views.

At Glaucoma 360 2025, Danica Marrelli, OD, FAAO, dove into the data on visual field testing for patients with glaucoma.

Attention to patients' near visual needs is warranted when choosing medications.

Walline, OD, PhD, FAAO, states that the best way to learn the benefits of artificial intelligence for your practice is to stay on top of continuing education attendance.

Now, the VTO platform features 3 different offerings, 2 which are new and 1 which has been updated, according to the company.

The CREST Registry study reported on the safety and effectiveness outcomes of microinvasive cyclodialysis clef formation with the CycloPen system, followed by scleral reinforcement with AlloFlo Bio-Tissue implantation, according to Iantrek.

The announcement comes after a request was made by the Canadian Investment Regulatory Organization (CIRO) to explore the possibility of a sale.

Misconceptions often lead to missed diagnoses.

Catch up on what happened in optometry during the week of February 3-February 7.

Jeffrey Walline, OD, PhD, FAAO, gives an overview of the AAO's 2024 and what to expect in 2025 and beyond.

The dynamic muscle stimulation device is a noninvasive option for patients experiencing lower lid laxity and impaired blinking.

The Sentinel Camera aims to address critical gaps in retinal disease screening by offering a portable device that captures high-quality images that require no dilation of the eye.

The company sits at spot 43 for “its outstanding performance in areas including unit growth, financial strength and stability, and brand power."

Annual reports of the occurrence of adverse effects associated with the use of cosmetics increased from 2006 to 2018, then decreased from 2018 to 2021.